Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial.

Eur J Heart Fail

Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.

Published: February 2022

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.2420DOI Listing

Publication Analysis

Top Keywords

early benefit
4
benefit empagliflozin
4
empagliflozin heart
4
heart failure
4
failure preserved
4
preserved ejection
4
ejection fraction
4
fraction insights
4
insights emperor-preserved
4
emperor-preserved trial
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!